Robert's Feed
Mar 24, 2015
via Breakingviews

Google’s CFO search should have it feeling lucky

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Google’s CFO search should have it feeling lucky. There’s a dearth of executives with the financial, tech and government know-how needed to help run a $400 billion company. Even fewer women fit the bill. Silicon Valley and Wall Street just can’t find people like Morgan Stanley Chief Financial Officer Ruth Porat fast enough. The challenge is to create more like her.

Mar 24, 2015
via Breakingviews

Google’s CFO search should have it feeling lucky

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Google’s CFO search should have it feeling lucky. There’s a dearth of executives with the financial, tech and government know-how needed to help run a $400 billion company. Even fewer women fit the bill. Silicon Valley and Wall Street just can’t find people like Morgan Stanley Chief Financial Officer Ruth Porat fast enough. The challenge is to create more like her.

Mar 16, 2015
via Breakingviews

Valeant’s $11 bln bid may have scored two knockouts

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The sweetened $11 billion bid by Valeant Pharmaceuticals for Salix Pharmaceuticals may have scored two knockouts. By stumping up an extra 10 percent from its previous offer, the acquisitive drugmaker now backed by hedge fund boss Bill Ackman put rival suitor Endo International on the mat. The extra cash required, and the debt already on its balance sheet, leave Valeant’s business model looking wobbly.

Mar 16, 2015
via Breakingviews

Valeant’s $11 bln bid may have scored two knockouts

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The sweetened $11 billion bid by Valeant Pharmaceuticals for Salix Pharmaceuticals may have scored two knockouts. By stumping up an extra 10 percent from its previous offer, the acquisitive drugmaker now backed by hedge fund boss Bill Ackman put rival suitor Endo International on the mat. The extra cash required, and the debt already on its balance sheet, leave Valeant’s business model looking wobbly.

Mar 6, 2015
via Breakingviews

Apple entry into DJIA is polish for an antique

Photo

By Robert Cyran and Richard Beales

The authors are Reuters Breakingviews columnists. The opinions expressed are their own.

Apple’s entry into the Dow Jones industrial average is a bit like polishing an antique. The average share price of 30 stocks selected by committee will finally include the world’s biggest company in place of AT&T. It’s an overdue move for an outdated yardstick – one which, like landlines and checkbooks, lives on.

Mar 6, 2015
via Breakingviews

Apple entry into DJIA is polish for an antique

Photo

By Robert Cyran and Richard Beales

The authors are Reuters Breakingviews columnists. The opinions expressed are their own.

Apple’s entry into the Dow Jones industrial average is a bit like polishing an antique. The average share price of 30 stocks selected by committee will finally include the world’s biggest company in place of AT&T. It’s an overdue move for an outdated yardstick – one which, like landlines and checkbooks, lives on.

Mar 5, 2015
via Breakingviews

AbbVie CEO may have overpaid again in $21 bln deal

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

AbbVie’s chief executive may have overpaid once again. Richard Gonzalez prompted the pharmaceutical giant to cough up $1.6 billion last year to free it from its bid for Irish drug manufacturer Shire. Now the company is paying $21 billion for biotech firm Pharmacyclics, after an intensely competitive auction. AbbVie may end up with a blockbuster medicine, but at too high a cost.

Mar 4, 2015
via Breakingviews

Actavis sale dresses up barely investment grade

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Actavis is showcasing the value of being barely investment grade. The acquisitive drugmaker attracted huge demand this week for $21 billion of bonds a mere notch above junk. They yield less than Verizon’s bigger and better-rated issue did in 2013. Buyers of top-tier debt can’t help but keep looking further downward.

Feb 23, 2015
via Breakingviews

Deal junkie Valeant shoots up on $10 bln fix

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Deal junkie Valeant Pharmaceuticals has shot up on a $10 billion fix. The drugmaker’s pledge last year to focus on organic growth and debt reduction didn’t last long. Cost cuts and tax savings from buying Salix Pharmaceuticals proved irresistible. What Valeant’s injecting isn’t clear, though. Salix’s numbers are fuzzy after it admitted pumping clients full of inventory.

Feb 12, 2015
via Breakingviews

Yahoo’s Alibaba spinoff attracts big discount

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Yahoo can’t even earn a reward for doing what shareholders wanted. The company’s plan for a tax-free spinoff of its stake in Alibaba looks logical. But a Breakingviews calculator suggests investors are attaching a 34 percent discount to the U.S. tech firm’s Alibaba shares – assuming, that is, Yahoo’s core business is worth something.

    • About Robert

      "Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University."
    • Follow Robert